592039 Disclosed is a pharmaceutical composition comprising: (i) a PDGF antagonist that is an antibody or binding fragment thereof； (ii) a VEGF-A antagonist that is an antibody or binding fragment thereof； and (iii) a pharmaceutically acceptable carrier, wherein the PDGF antagonist and the VEGF-A antagonist are present in an amount that is effective for treating a neovascularization disorder. Further disclosed is the use, in the manufacture of a medicament, of (i) a PDGF antagonist that is an antibody or binding fragment thereof； and (ii) a VEGF-A antagonist that is an antibody or binding fragment thereof, for treating or preventing an ocular neovascular disorder. Further disclosed is a pharmaceutical combination comprising: (i) a PDGF antagonist that is an antibody or binding fragment thereof； and (ii) a VEGF-A antagonist that is an antibody or binding fragment thereof, wherein the PDGF antagonist and the VEGF-A antagonist are formulated in an amount that is effective for treating a neovascularization disorder and formulated for sequential or simultaneous administration.
